Teva Has a Biopharma Margin and a Generic Top Line
The Q3 report was a mix story, not a growth story — and the next real revenue catalyst, WELTRUZA, is a 2027 event.
TEVA · Earnings Call · 2026-11-03
The margin is the message
Teva's Q3 2026 call opens with a deliberate paradox. Revenue fell 2% to $4.4B, yet management sounded more confident than at any point in the past three years. The reason sits below the top line: management highlighted gross margin at 58.7%, up 345 bps on Richard Francis's framing, and non-GAAP EPS rose 10% to $0.86. “Revenues declined 2%, but our gross margin grew to 58.7%. That is up 345 basis points.” — Richard Francis, CEO · 2026-11-03 Francis wants investors to read this as proof that the biopharma company transition is no longer a slide deck.
This is not a one-quarter effect. It reflects deliberate choices we have made to transition the business. We set out in 2023 to become a biopharma company, and these results show that transformation is happening. What I would highlight is there is more to come.
The equity has already voted. TEVA is up 22.5% in 90 days and still 41.8% below its 2015 peak, but the valuation has left generic territory. 2.8x revenue, up 142% year over year. In the last filed quarter, revenue was $4.1B, down 1% yoy and 40% below the 2017 peak. That is the central tension: margins are inflecting, revenue is not.
The mix shift is stark. Innovative products grew 33%; Generic revenues fell 16%, largely on the loss of generic REVLIMID. This is a company-specific self-help story, not a broad market wave. The global keyword tape is dominated by tariffs, AI infrastructure and rate cycles; Teva's re-rating is about its own P&L mix.
The growth engine is narrow — and the next launch is a 2027 event
The growth is real but concentrated: AUSTEDO $751M, +21%; UZEDY $85M, +96%; AJOVY $269M, +61%. Guidance was raised across all three. But AUSTEDO's 2027 path runs through the IRA impact. On the call, an analyst tried to size the Medicare exposure at roughly $0.5B; Francis did not give formal guidance but conceded the arithmetic: “technically speaking, yes, you're right. That's probably the first thing to say.” — Richard Francis, CEO · 2026-11-03 That is a subtle shift from prior calls, when the company hid behind the negotiation process and said only that all Medicare plans must cover negotiated products. “all Medicare plans are required to cover negotiated products in their Part D formularies.” — Richard Francis, Chief Executive Officer · 2026-07-29 The confidence is still there — Francis reiterated $2.5B for AUSTEDO next year and more than $3B at peak — but the IRA is now a number to manage, not a topic to avoid.
The bigger near-term issue is WELTRUZA. The olanzapine LAI was approved in October, but the launch will not produce meaningful revenue in Q4; initial volume is samples and vouchers. “on WELTRUZA, revenue expectations are in the latter half of the year.” — Richard Francis, CEO · 2026-11-03 The gating factor is Medicaid formulary access; at 12 months, management expects about 85% coverage. So the stock is pre-paying a 2027 launch. ecopipam is another Q1 2027 approval, and BXCL501 is a $57.5M upfront tuck-in that will take longer. The pipeline is real, but the revenue is back-end loaded.
The call also had a crack in the R&D narrative: emrusolmin was discontinued after a futility analysis. “we have discontinued the phase II study.” — Richard Francis, CEO · 2026-11-03 Management framed it as disciplined capital allocation and said future bets will favor higher-probability assets. That is credible, but it is a reminder that the R&D Day next week is a catalyst, not a guarantee.
Biosimilars are filling the generic hole — just not yet
The generics franchise is not standing still. Excluding generic REVLIMID, global generics grew 1%; Europe grew 7%. Biosimilars are the most tangible offset: Teva now expects to hit $800M in biosimilar sales in 2026, a year ahead of the 2027 target. On the prior call, Francis was already signaling the pull-forward: “We did set ourselves a target for $800 million by 2027, as I said today on the call. We're well on track to exceed that already.” — Richard Francis, Chief Executive Officer · 2026-07-29 The portfolio now stands at 15 products, with 32 including the new Samsung partnership, and three of five U.S. biosimilars are ranked number one.
But biosimilars come with litigation. Analysts pressed on biosimilar SIMPONI, XOLAIR and ENTYVIO. Francis was candid: “we strategically plan, and we financially plan with realism.” — Richard Francis, CEO · 2026-11-03 That is the right posture, but it also means the generic hole is being filled by a portfolio with binary legal outcomes. The base generics business is still guided to flat-to-slightly-up in 2026 and only 1-2% long-term growth. Biosimilars improve the mix; they do not yet replace REVLIMID.
The balance sheet is the quiet enabler
The other milestone is investment grade. Teva now has investment-grade ratings from all three major agencies, refinanced $4.9B of senior notes, repaid $1.8B of debt in October, and remains on a path to 2x net debt/EBITDA by 2027. Eli Kalif put the capital return in context: the company has repaid about $12B of debt since 2019 and expects roughly $2.7B of free cash flow in 2027 against less than $1B of annual maturities from 2028-2030. The direct New York Stock Exchange ordinary-share listing is part of the same story: a broader investor base, a lower cost of capital, and a cleaner equity story.
The balance sheet is better, not pristine. The last filed quarter still showed negative $845M effective net cash, and liabilities were 80.5% of assets. The improvement is real; the absolute level is not yet comfortable.
Bottom line
Teva has won the argument on mix. The gross margin, the investment-grade rating, and the biosimilar pull-forward are all evidence that the pivot is more than a slogan. But the top line is still shrinking, the growth engine is three products, and the next major launch will not contribute until the second half of 2027. The stock has moved first. The question for the next two quarters is whether 2027 guidance validates the multiple. Francis himself provided the right caution on an earlier call: “let's get some more quarters under our belt before we start predicting what the future could be.” — Richard Francis, CEO · 2026-04-29 The margin has changed. The revenue still has to prove it.